{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-015153","form_type":"8-K","ticker":"OMDA","cik":"0001611115","company_name":"Omada Health, Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.641053+00:00","generated_at":"2026-05-15T19:40:24.420911+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Omada Health Q4 revenue $76M (+58% YoY), achieves positive net income of $5M","bullets":["Q4 revenue $76M (+58% YoY); full-year $260M (+53% YoY). GAAP net income $5M in Q4 vs ($8M) loss prior year.","Full-year net loss narrowed to $13M from $47M; adjusted EBITDA turned positive at $6M vs ($29M) in 2024.","Total members reached 886,000 (+55% YoY); GLP-1 supported members tripled to over 150,000.","Gross margin improved: Q4 GAAP 71% (up from 67%), full-year 66% (up from 61%).","Launched new products: GLP-1 Flex Care, OmadaSpark, Meal Map, and Omada for Cholesterol (Feb 2026)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-015153","json":"https://secwatch.observer/filing/0001628280-26-015153.json","markdown":"https://secwatch.observer/filing/0001628280-26-015153.md","text":"https://secwatch.observer/filing/0001628280-26-015153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1611115/000162828026015153/0001628280-26-015153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1611115/000162828026015153/omda-20260305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:40:24.420911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c049ccb00f0d6d6db5f256e32ffaecd2d6d168e4","claim":"Omada Health, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $76 million, net income $5 million.","evidence_excerpt":"Revenue • $76 million in the fourth quarter, up 58% year over year • $260 million for the full year, up 53% compared with 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1611115/000162828026015153/0001628280-26-015153-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2025"},{"label":"Revenue","value":"$76 million"},{"label":"Net income","value":"$5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c839efe7160af61da869c55b6ea39a5383f149de","claim":"Omada Health, Inc. reported the full year ended December 31, 2025 results: revenue $260 million, net income net loss of $13 million.","evidence_excerpt":"and full year 2025, except where otherwise noted. Total members • 886,000 at year end, up 55% year over year Revenue • $76 million in the fourth quarter, up 58% year over year • $260 million for the full year, up 53% compared with 2024 GLP-1 Leadership • Omada has now supported more than 150,000 members on GLP-1s, compared with more than 50,000 at the end of 2024 •","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1611115/000162828026015153/0001628280-26-015153-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2025"},{"label":"Revenue","value":"$260 million"},{"label":"Net income","value":"net loss of $13 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}